Immunic (NASDAQ:IMUX) Upgraded by Lifesci Capital to "Strong-Buy" Rating

Key Points

• Lifesci Capital upgraded Immunic to a "strong-buy", and the Street consensus remains a "Buy" with an average target price of $52.43 (analytics: 3 Strong Buy, 6 Buy, 1 Hold, 1 Sell).
• Shares rose about 10.1% to open at $10.62, giving the company a market capitalization near $144.6 million and a one‑year trading range of $5.06–$15.10.
• Immunic is a clinical‑stage biopharma whose lead candidate, vidofludimus calcium (IMU‑838), is in Phase 2, but it recently missed quarterly EPS estimates and analysts project roughly -3.44 EPS for the current year.

Immunic (NASDAQ:IMUX - Get Free Report) was upgraded by investment analysts at Lifesci Capital to a "strong-buy" rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Several other equities analysts have also recently weighed in on IMUX. Guggenheim started coverage on Immunic in a research note on Tuesday, March 24th. They set a "buy" rating and a $70.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and set a $22.00 target price (up from $5.00) on shares of Immunic in a research note on Thursday. Wall Street Zen cut Immunic from a "hold" rating to a "sell" rating in a research note on Sunday, April 19th. D. Boral Capital cut Immunic from a "buy" rating to a "hold" rating in a research note on Wednesday, April 15th. Finally, Stifel Nicolaus set a $25.00 target price on Immunic and gave the company a "buy" rating in a research note on Thursday, April 16th. Three analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $52.43.

Immunic Trading Up 10.1%

Shares of IMUX opened at $10.62 on Monday. The business's 50-day moving average price is $11.07 and its 200 day moving average price is $8.40. The stock has a market capitalization of $144.64 million, a P/E ratio of -1.52 and a beta of 1.20. Immunic has a 1-year low of $5.06 and a 1-year high of $15.10.

Immunic (NASDAQ:IMUX - Get Free Report) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($1.20) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.18). On average, research analysts predict that Immunic will post -3.44 earnings per share for the current year.

Institutional Investors Weigh In On Immunic

Several large investors have recently made changes to their positions in the company. Qube Research & Technologies Ltd bought a new stake in shares of Immunic in the 3rd quarter valued at approximately $29,000. Focus Partners Wealth grew its stake in shares of Immunic by 1.5% in the 3rd quarter. Focus Partners Wealth now owns 2,581,587 shares of the company's stock valued at $2,276,000 after buying an additional 39,063 shares in the last quarter. Two Sigma Investments LP bought a new stake in shares of Immunic in the 3rd quarter valued at approximately $52,000. Squarepoint Ops LLC grew its stake in shares of Immunic by 29.9% in the 4th quarter. Squarepoint Ops LLC now owns 352,875 shares of the company's stock valued at $188,000 after buying an additional 81,301 shares in the last quarter. Finally, Jane Street Group LLC grew its stake in shares of Immunic by 46.8% in the 4th quarter. Jane Street Group LLC now owns 286,677 shares of the company's stock valued at $153,000 after buying an additional 91,346 shares in the last quarter. Institutional investors own 51.82% of the company's stock.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company's research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic's lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn's disease and relapsing multiple sclerosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.